WASHINGTON, July 31 The U.S. Food and Drug
Administration said on Thursday it has approved Boehringer
Ingelheim's drug to treat chronic obstructive pulmonary disease
(COPD), an umbrella term that includes chronic bronchitis and
The drug, Striverdi Respimat, known also as olodaterol, is
one of a class of drugs known as long-acting beta-adrenergic
agonists (LABAs) that relax airways in the lungs to ease
wheezing, cough and shortness of breath.
The drug will carry a boxed warning that LABAs can increase
the risk of asthma-related death. The drug is not approved to
treat asthma. COPD, which is usually caused by smoking, is the
third leading cause of death in the United States.
(Reporting by Toni Clarke; Editing by Bill Trott)